Novo Holdings A/S’s Rocket Pharmaceuticals RCKT Stock Holding History

Novo Holdings A/S’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,100,000	Closed	-$7.34M	–	32
2025 Q1	$7.34M	Hold	1,100,000	–	–	0.56%	23
2024 Q4	$13.8M	Hold	1,100,000	–	–	0.84%	23
2024 Q3	$20.3M	Hold	1,100,000	–	–	1.01%	25
2024 Q2	$23.7M	Buy	1,100,000 +50,000	+5%	+$1.15M	1.28%	27
2024 Q1	$28.3M	Hold	1,050,000	–	–	1.95%	18
2023 Q4	$31.5M	Buy	1,050,000 +49,000	+5%	+$1.08M	1.94%	20
2023 Q3	$20.5M	Buy	1,001,000 +81,000	+9%	+$1.47M	1.52%	26
2023 Q2	$18.3M	Hold	920,000	–	–	1.41%	25
2023 Q1	$15.8M	Buy	920,000 +70,000	+8%	+$1.37M	1.04%	28
2022 Q4	$16.6M	Buy	850,000 +217,178	+34%	+$4M	1.04%	25
2022 Q3	$10.1M	Hold	632,822	–	–	0.48%	37
2022 Q2	$8.71M	Buy	632,822 +20,000	+3%	+$238K	0.43%	41
2022 Q1	$9.72M	Hold	612,822	–	–	0.51%	34
2021 Q4	$13.4M	Buy	612,822 +78,737	+15%	+$2.15M	0.63%	27
2021 Q3	$16M	Buy	+534,085	New	+$19.4M	0.83%	26

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Novo Holdings A/S's RCKT Position: Q2 2025 in Review

Novo Holdings A/S sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 1,100,000 shares — an estimated $7.34M sold.

Novo Holdings A/S first reported a position in RCKT in Q3 2021 and held it in 15 quarters. The position peaked at $31.5M in Q4 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

Novo Holdings A/S reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Novo Holdings A/S sold 1,100,000 Rocket Pharmaceuticals shares in Q2 2025, an estimated $7.34M.
Novo Holdings A/S first reported a position in Rocket Pharmaceuticals in Q3 2021 and held it in 15 quarters.
Novo Holdings A/S's Rocket Pharmaceuticals position peaked at $31.5M in Q4 2023.
196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Novo Holdings A/S's 13F filing for Q2 2025, filed 14 Aug 2025.